RUBINSTEIN JULIE

ADPT President/COO Rubinstein sells 57,180 shares in 3 trades (Apr 22-24) for $798,423.40; post-transaction holdings: 382,132 shares (-13.0%).

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed 3 separate sales totaling 57,180 shares for $798,423.40 between April 22 and April 24, 2026, at an average price of $13.96 per share. Her post-transaction holdings of 382,132 shares represent a -13.0% reduction from the 439,312 shares she held before these sales. The stock currently trades at $14.14, near the transaction prices, and is down 30.9% from its 52-week high of $20.46, suggesting a period of price deterioration despite the company's strong quarterly revenue of $93,973,000.00 and annual revenue growth of 54.8%. This sale activity occurs within a pattern of frequent selling activity at ADPT (5 prior trades in the same ticker within days of this filing), though outcomes on those prior trades are not yet measurable given their recent timing.

ADPT President/COO Rubinstein sells 69,061 shares for $1.0M across three days at $14.55–$14.66

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed 3 separate sales totaling 69,061 shares for $1,008,622.26 between April 17–21, 2026, at prices ranging from $14.55 to $14.66. The blended average price of $14.60 sits at -30.6% from the 52-week high of $20.46, and the current price of $14.21 is now below all three transaction prices. Post-transaction holdings of 395,146 shares represent a 14.9% reduction from pre-transaction levels. The sale occurred against a backdrop of recent consecutive daily sales at ADPT (5 prior trades within days, all sells), though outcomes on those near-term sales remain unmeasurable. The company's fundamentals show strong quarterly revenue of $93,973,000.00 and positive net income of $9,546,000.00, but the P/E of 109.31 and elevated market cap of $2,188,077,981.81 reflect a high-growth profile rather than deep value. The pattern of rapid consecutive liquidations by a senior executive warrants attention to whether operational or personal liquidity considerations are driving the activity, particularly given the elevated valuation multiples.

ADPT President/COO Rubinstein sells 57,180 shares in 3 transactions (Apr 14-16) for $826,251 at blended $14.45 avg; holds 408,160 post-sale amid 5 consecutive prior sells.

Julie Rubinstein executed 3 separate sales totaling 57,180 shares for $826,251.00 between April 14-16, reducing her holdings by -12.3% to 408,160 shares. This multi-day sequence is notable because it follows a pattern of 5 consecutive prior sales at ADPT within the preceding week (April 9–13), suggesting sustained liquidation activity rather than an isolated transaction. The transactions occurred at prices ranging from $14.18 to $14.61, compared to the current price of $14.08, placing them in the upper half of the 52-week range ($6.83–$20.46) and near recent highs. Context warrants scrutiny: while Adaptive Biotechnologies shows strong quarterly fundamentals (Revenue $94.0M, +54.8% annual growth, Net income $9.5M), the company's elevated P/E of 108.31 and prior full-year unprofitability underscore valuation tensions that may influence executive positioning.

President and COO Rubinstein sells 57,180 shares for $758,108.34 across 6 transactions in April; stock at -30.9% from 52-week high

Julie Rubinstein, President and COO, executed 6 separate sales totaling 57,180 shares (57.2K shares) for $758,108.34 between April 6–13, 2026, at an average price of $13.26, reducing her holdings by -12.0%. This substantial disposition by a C-suite executive occurs while the stock is trading 30.9% below its 52-week high of $20.46 and has declined 21.8% over the past 90 days, despite a recent 30-day bounce of +7.3%. The company's fundamentals show strong revenue growth of 54.8% year-over-year and recent quarterly net income of $9.5M, though it reported negative full-year net income in its most recent fiscal year and carries a high P/E of 108.69. The timing of these sales—while the stock is down significantly from its peak and the company's profitability profile remains mixed—may warrant attention to whether Rubinstein's disposition signals a divergence between executive view and current valuation, though her cross-ticker sell track record (20 prior sells with an average 30-day return of -1.3%) does not establish a consistent pattern of prescient timing.

ADPT President/COO Rubinstein sells 69,061 shares in 4 transactions for $990,503.43; extends 5-trade selling streak in early April.

Julie Rubinstein executed 4 separate sales totaling 69,061 shares over three days (April 6–8, 2026) at prices ranging from $13.56 to $15.48, for a blended average of $14.34 and total proceeds of $990,503.43. This sale reduced her holdings by 13.7% (from 503.2K to 434.2K shares). The transaction is part of a concentrated selling sequence: SAME-TICKER HISTORY shows 5 consecutive sell transactions at ADPT in the preceding week (March 27 through April 2), all with outcomes not yet measurable. The stock is currently trading at $14.84, within 27.5% of its 52-week high ($20.46), and the company posted strong recent fundamentals (FY revenue growth of 54.8%, latest quarter revenue of $94.0M, latest quarter net income of $9.5M), though full-year net income was negative. The sustained, multi-day selling pattern by the President and COO warrants attention as a signal of near-term portfolio adjustment in an executive with material holdings, independent of whether it reflects broader strategic concerns.

President and COO Julie Rubinstein sells 38,120 shares across 2 separate sales for $553,693.00; holds 447,202 shares post-transaction amid -7.9% 30-day decline.

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed two separate open-market sales on consecutive trading days (April 1–2, 2026), totaling 38,120 shares for $553,693.00 at an average price of $14.52. The stock now trades at $14.81, only $0.29 above her blended transaction price, while the 30-day trend is -7.9% and the stock sits -27.6% from its 52-week high of $20.46. Her holdings of 447,202 shares represent a -7.9% reduction from her pre-transaction position. The company's underlying financial position is mixed: it reported $94.0M in quarterly revenue with 54.8% annual growth and positive net income of $9.5M in the latest quarter, yet remains unprofitable on a full-year basis and carries a high P/E of 113.92 at a $2.3B market cap. Notably, Rubinstein executed five separate sales within the prior week (March 26–31), all of which remain too recent to assess 90-day outcomes. The concentrated selling pattern in this high-growth, recently unprofitable biotech warrants attention to any concurrent earnings or strategic announcements.

ADPT President and COO Rubinstein sells 57,180 shares across 4 transactions for $751,302.98 (blended avg $13.14)

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed 4 separate sales totaling 57,180 shares (57.2K shares) for $751,302.98 between March 27–31, 2026, with a blended average price of $13.14. This represents an 11.1% reduction in her post-transaction holdings to 455,878 shares (455.9K shares). The current stock price of $13.88 stands 32.2% below the 52-week high of $20.46, and the stock has declined 13.4% over the past 30 days and 14.5% over the past 90 days. Rubinstein's SAME-TICKER HISTORY shows 5 recent consecutive sales (March 20–26) immediately preceding this filing, all with outcomes not yet measurable, and her cross-ticker TRACK RECORD of 20 prior sells has produced 0 well-timed outcomes at the 90-day mark. The company's fundamentals are mixed: revenue of $93,973,000.00 (latest quarter) reflects strong annual growth of 54.8%, but the P/E ratio of 106.77 is elevated, and the company was unprofitable over its most recent full fiscal year despite quarterly net income of $9,546,000.00.

ADPT President & COO sells 57,180 shares across 3 days for $802,235.40; stock down 31.8% from 52-week high

Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares (57.2K shares) across three separate transactions on March 24–26, 2026, at prices ranging from $13.70 to $14.27, realizing $802,235.40 total and reducing her holdings by 10.9% to 468,892 shares. The stock has declined 31.8% from its 52-week high of $20.46 and is down 13.0% over the past 30 days, while the company's recent fundamentals show substantial revenue growth of 54.8% year-over-year and positive net income of $9,546,000.00 in the latest quarter, though it remains unprofitable on a full-year basis with a P/E ratio of 107.38. This multi-day sale by a senior executive occurs during a period of significant stock price weakness and follows five prior ADPT sells by Rubinstein in the preceding trading days (March 17–23), establishing a pattern of repeated liquidation at depressed valuations relative to the 52-week range. The rapid succession of six sales in ten calendar days, combined with the company's high valuation multiple despite full-year losses and the stock's sharp recent decline, may warrant investor attention to whether this liquidation reflects differing views on near-term prospects or execution strategy.

President & COO Rubinstein sold 57,180 shares in 3 tranches (Mar 19-23) for $769,642.80 at $13.46 avg; stock now -33.2% from 52-week high.

Julie Rubinstein, President and COO, executed 3 separate sales totaling 57,180 shares for $769,642.80 over a four-trading-day period (March 19–23), reducing her holdings by -10.6% to 481,906 shares. The transactions occurred at prices ranging from $13.18 to $13.83, establishing a blended average price of $13.46, which was within the company's recent trading range but below the current price of $13.66. Against the broader context, ADPT has declined 33.2% from its 52-week high of $20.46 and trades at a P/E of 105.08 on a market cap of $2.1B, despite recent-quarter revenue of $94.0M with strong annual growth of +54.8%. This execution occurred during a period of significant price compression: the stock has fallen 10.1% over 30 days and 18.4% over 90 days. Rubinstein's sale pattern—five consecutive selling days in a compressed window mid-to-late March—merits attention as a concentrated exit rather than a gradual diversification, particularly given the equity's elevated valuation multiple relative to profitability metrics.

ADPT President and COO Rubinstein sold 57,180 shares across 3 days at $13.18–$13.41 as stock falls 35.1% from 52-week high

Julie Rubinstein, President and COO of Adaptive Biotechnologies, executed 3 separate sales totaling 57,180 shares (57.2K shares) for $762,209.40 ($762.2K) on 2026-03-16 through 2026-03-18, reducing her holdings from 552,100 shares to 494,920 shares (-10.4%). The sales occurred at a blended average price of $13.33, within a narrow window as the stock traded between $13.18 and $13.41 across the three days. The company's stock is trading at $13.28, representing a -35.1% decline from its 52-week high of $20.46 and a -17.2% drop over the prior 30 days. While Adaptive Biotechnologies reported strong recent fundamentals (revenue of $93,973,000 with +54.8% annual growth and net income of $9,546,000), the company remains unprofitable on a full-year basis despite its elevated P/E of 102.15. Rubinstein's prior trades at ADPT have not yet accumulated measurable outcomes, limiting the ability to assess the timing pattern of this transaction at this ticker specifically.